Russia

According to the FDA Report, Russia placed in the top 10 and ranked 2nd after the U.S. in terms of the number of subjects recruited. Russia is the world's 9th country by population (146 mln people), making it a patient pool more than sufficient for a study in almost any indication.

Czech Republic

The leading therapeutic areas in terms of the approvals in 2021 were Oncology, Neurology, Cardiology, Rheumatology. Besides, the country offers competitive advantages for trials in niche areas such as rare and orphan diseases, stem cell and gene therapies.

Hungary

Clinical trials in Hungary are in high demand, as the region is a unique combination of all the important aspects: fast enrollment, low prices, and a remarkable level of quality. Out 50 novel drugs approved by the FDA in 2021, 14 have undergone studies at Hungarian sites.

Spain

Today 145,000 patients are involved in 3,400 clinical trials in progress in Spain. While one out of three trials carried out in Europe already has Spanish participation, the country accounts for a 4.3% share of the global clinical trials activity with oncology as the leading therapeutic area.

Bulgaria

In 2014-2019 Bulgaria was placed in the top 10 and ranked 8th in terms of the number of subjects recruited for studies according to the recent US FDA Report. 13 out of 50 novel drugs approved by the FDA in 2021 underwent studies in Bulgaria.

Romania

Romania has been drawing a lot of interest for international Sponsors. The 12th largest state in Europe offers speedy start-up, specialized healthcare services, experienced personnel with advanced knowledge of eClinical solutions, and record recruitment rates across various therapeutic areas.

Poland

Poland is 10th place in the world by number of research sites (over 1,400). With a population of 38.5 mln people, it boasts successful recruitment rates, reasonable grants, and lower costs per patient than in the U.S., though higher than in Ukraine, Russia or Georgia.

Latvia

Being an EU member since 2004, Latvia boasts a harmonized regulatory and legislative environment for international clinical trials. The majority of studies fall within the therapeutic areas of oncology, neurology, psychiatry, and endocrinology.

Belarus

Belarus is a promising new player. Clinical research professionals are very particular about adhering to GCP standards. Local rules and standards are very close to those mandated by FDA and EMA.

Ukraine

Recruitment shows a significant number of eligible patients, including treatment-naïve ones. According to the MoH of Ukraine, leading therapeutic areas in 2020 are Oncology, Psychiatry, Neurology, Gastroenterology, and Hematology. The RA process takes up to 60 calendar days.

Seit 2005 erbringen wir hochwertige CRO Services in Osteuropa

18 internationale Standorte rund um den Globus

Kontaktieren Sie unser Regionalbüro

Tätigkeit in 18 Ländern:

Lettland
Polen
Rumänien
Ungarn
Tschechische Republik
Spanien
Ukraine
Bulgarien
Niederlande
Georgien
Estland
Litauen
Belarus
Serbien
Russland
Kasachstan
Kroatien
Moldawien

Weitere Länder

An official member of the European CRO Federation

Schauen Sie sich die Ausgabe von Industry Voice “ACM Biosciences erklärt Impfstoffentwicklung”

Free Feasibility Report Anfrage senden

Schauen Sie sich die Ausgabe von Industry Voice “ACM Biosciences erklärt Impfstoffentwicklung”

Free Feasibility Report Andfrage senden

bis zu

schnellere patientrekrutierung

zugang zu

2,100

führenden forschungseinrichtungen

wir haben

58,937

patienten aufgenommen

wir liefern

EMA/FDA

akzeptable daten

Tailored approach to every project ●

1.5 x faster enrollment rate for any area ●

An email or a phone call away ●

Vollständiges Angebot an Dienstleistungen für klinische Studien

Vorbereitung Der Klinischen Studie

Medizinisches Schreiben

Beratung und regulatorische Unterstützung

Arzneimittelsicherheit und Pharmakovigilanz

Projektmanagement und Kontrolle

Verarbeitung von klinischen Daten

Biostatistik

Unterstützung im Bereich Logistik

Bei der Wahl zwischen Qualität, Zeitplan und Budget geben wir uns niemals mit einem Kompromiss zufrieden. Wir liefern immer das Beste in allen drei Bereichen.

Gatis Klaucans
Director of Clinical Operations, OCT Latvia

Über 300 Studien in 29 therapeutischen Feldern
seit 2005

OCT Clinical als Retter in Not

Rettungsstudien als besondere Kompetenz

Wenn klinische Studien auf Hindernisse stoßen, sind wir bereit, einzugreifen. Jedes Mal, wenn wir eine aktive Studie übernehmen, erstellen unsere Experten einen Rettungsplan für die Studie, der sich auf die Behebung aktueller Engpässe und Studienherausforderungen konzentriert, sowie einen beschleunigten Studienplan, um die Studie wieder auf Kurs zu bringen.

Rückruf anfordern